Develops oral drugs for inflammatory and proliferative diseases.
Mar 2025Revenue $7.57M/yrExpenses $35.6M/yr
No trendCash runway ≈ 8 months from Jun 2026
Figures by year
When will Tvardi Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2025, revenue was $7.57M and expenses $35.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $7.14M | $35.2M | −$28.1M |
| Dec 2023 | $21.0M | $142M | −$121M |
| Dec 2022 | $41.9M | $129M | −$87.5M |
| Dec 2021 | $23.0M | $112M | −$89.1M |
| Dec 2020 | $135M | $130M | $5.38M |
| Dec 2019 | $19.9M | $132M | −$112M |
| Dec 2018 | $13.5M | $90.9M | −$77.4M |
| Dec 2017 | $911K | $60.4M | −$59.5M |
| Dec 2016 | $86.0K | $58.5M | −$58.4M |
| Dec 2015 | $3.80M | $29.0M | −$25.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.